C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients

PURPOSE: Overall survival (OS) is the most significant endpoint for evaluation of treatment benefit with checkpoint inhibitors (CPI) in cancer. We evaluated serum C-reactive protein (CRP) in non-small cell lung cancer (NSCLC) trials with atezolizumab (anti-PD-L1) as an early OS surrogate. METHODS: S...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: Patil, Namrata S., Zou, Wei, Mocci, Simonetta, Sandler, Alan, Ballinger, Marcus, Flynn, Susan, Kowanetz, Marcin, Hegde, Priti S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2021
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7857603/
https://ncbi.nlm.nih.gov/pubmed/33534859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0246486
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller